Shenzhen Capital Group Co-Leads $62M Round In Chinese Biopharmaceutical Firm Zelgen

Login to View

Shenzhen Capital Group Co., Ltd, Minsheng Life Insurance and Share Capital have led a RMB400 million (US$62 million) series B round in Suzhou Zelgen Biosciences Co., Ltd., a Chinese biopharmaceutical company.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Read 3 Articles for Free with a Basic Account

Gain limited and restricted access to China Money Network.

Register Basic Account

Subscribe for an annual subscription for $359

Enjoy comprehensive and exclusive data you can't find elsewhere!

Subscribe for $359

Subscribe and Pay Easily Online!

Already have an account or paid subscription? Log in